Welcome to our dedicated page for TREVENA news (Ticker: TRVN), a resource for investors and traders seeking the latest updates and insights on TREVENA stock.
Trevena, Inc. (Nasdaq: TRVN) is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies targeting G protein-coupled receptors (GPCRs). The company's mission is to improve patient outcomes and reduce healthcare costs through novel therapies. Trevena's pipeline includes four key drug candidates:
- TRV130 (OLINVYK®): An FDA-designated breakthrough therapy for the intravenous treatment of acute moderate to severe pain, currently in Phase 3 testing. Recently, OLINVYK's effectiveness was assessed in the VOLITION study, showing promising results in terms of respiratory, gastrointestinal, and cognitive function outcomes in postoperative settings.
- TRV027: Evaluated in a Phase 2b study for treating acute heart failure, this candidate aims to address unmet needs in cardiovascular treatment.
- TRV734: Completed Phase 1 testing for the oral treatment of acute and chronic pain, TRV734 seeks to provide a non-opioid alternative for pain management.
- TRV250: In preclinical development for migraine treatment, focusing on innovative solutions for CNS disorders.
Trevena's pipeline is based on Nobel Prize-winning research, emphasizing its commitment to pioneering medical advancements. The company has collaborations with prominent institutions like Wake Forest Baptist Health and the Cleveland Clinic, ensuring rigorous evaluation and development of its therapies. Trevena is also exploring TRV045 for diabetic neuropathic pain and epilepsy, showcasing the potential impact beyond pain management.
Financially, Trevena has shown resilience, recently reporting a net loss reduction and strengthening its balance sheet with significant capital injections. The company continues to focus on strategic partnerships and innovative research to maintain its competitive edge in the biopharmaceutical industry.
For more information, please visit www.Trevena.com.
Rhea-AI Summary
Trevena, Inc. (Nasdaq: TRVN) announced promising results of TRV045 in nonclinical models of neuropathic pain, targeting the S1P1 receptor without causing lymphopenia. The poster presentation at the 62nd Annual Meeting for the American College of Neuropsychopharmacology discussed the potential utility of TRV045 for the treatment of chemotherapy-induced peripheral neuropathy (CIPN) and its collaboration with the NIH to evaluate TRV045 for epilepsy and nonopioid pain treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.39%
Tags
-
Rhea-AI Summary
Trevena Inc. (Nasdaq: TRVN) has secured a national group purchasing agreement for OLINVYK with Premier, Inc., effective December 1, 2023. Premier members now have the option to benefit from special pricing and terms pre-negotiated for OLINVYK, a significant development for the company's commercialization efforts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.39%
Tags
-
Rhea-AI Summary
Trevena, Inc. (Nasdaq: TRVN) announced the acceptance of the RELIEVE study abstract at the 2024 ABA Annual Meeting. The study focused on evaluating OLINVYK for patients with acute burn injuries. Results will be presented in April 2024. Dr. David Hill led the single-center trial, comparing OLINVYK with other IV opioids.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
Rhea-AI Summary
Trevena, Inc. (Nasdaq: TRVN) reported promising proof-of-concept data for TRV045 studies, favorable safety and tolerability topline data, and a strengthened balance sheet with a $15 million R-Bridge tranche. TRV045 demonstrated CNS target engagement and encouraging overall results in two proof-of-concept studies. Three OLINVYK abstracts were presented at ASA. The Company received a $15 million tranche from ex-US royalty-based financing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
-
Rhea-AI Summary
Trevena, Inc. (Nasdaq: TRVN) to Release Third Quarter 2023 Financial Results and Host Conference Call & Webcast at 8:00 a.m. ET. The company will discuss financial performance and future prospects, featuring remarks by key executives and a renowned medical expert. Investors can access the webcast via the provided links.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.15%
Tags
-
Rhea-AI Summary
Trevena, Inc. completes initial analysis of OLINVYK respiratory monitoring data from VOLITION study, to be presented at ASA meeting in October. No drug-related serious adverse events (SAEs) or deaths reported. Study shows potential positive impact on respiratory outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
News
Rhea-AI Summary
Trevena, Inc. receives $15 million tranche from ex-US royalty-based financing triggered by first commercial sale of OLINVYK in China. New respiratory data from VOLITION study expected in 3Q 2023. Three OLINVYK abstracts accepted for presentation at ASA Meeting in 4Q 2023. Company to participate in HC Wainwright conference. Conference call on September 6 to discuss TRV045 data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.29%
Tags
-
Rhea-AI Summary
Trevena, Inc. announces preliminary topline data from two Phase 1 proof-of-concept studies of TRV045, a novel sphingosine-1-phosphate receptor modulator selective for the S1P receptor subtype 1. Data shows statistically significant analgesic effect in capsaicin-induced model of neuropathic pain and evidence of CNS activity as measured by EEG power spectral analysis. Full safety and tolerability data expected in early 4Q 2023. Company to hold conference call on September 6 at 8 a.m. Eastern.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.29%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.83%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the current stock price of TREVENA (TRVN)?
The current stock price of TREVENA (TRVN) is $1.86 as of January 22, 2025.
What is the market cap of TREVENA (TRVN)?
The market cap of TREVENA (TRVN) is approximately 1.3M.
What is Trevena, Inc.?
Trevena, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies targeting GPCRs to improve patient outcomes and reduce healthcare costs.
What is OLINVYK®?
OLINVYK® (TRV130) is an FDA-designated breakthrough therapy for the intravenous treatment of acute moderate to severe pain, currently in Phase 3 testing.
What recent developments has Trevena announced?
Trevena recently reported promising results from the VOLITION study, assessing OLINVYK’s impact on respiratory, gastrointestinal, and cognitive functions in postoperative settings. They also received capital injections to strengthen their financial position.
What is TRV045?
TRV045 is an investigational drug for diabetic neuropathic pain and epilepsy, showing a favorable safety and tolerability profile in recent studies.
How is Trevena's financial performance?
Trevena has shown improved financial performance by reducing net loss and securing significant capital injections, positioning itself for future development and growth.
What types of products does Trevena develop?
Trevena focuses on novel therapies for acute and chronic pain, migraine treatment, heart failure, and CNS disorders, leveraging cutting-edge research and strategic collaborations.
Are Trevena's products FDA approved?
OLINVYK® is FDA-designated as a breakthrough therapy for acute pain, while other candidates like TRV045, TRV250, and TRV734 are in various stages of clinical and preclinical testing.
What partnerships does Trevena have?
Trevena collaborates with institutions like Wake Forest Baptist Health and the Cleveland Clinic to ensure rigorous evaluation and development of its therapies.
Where can I find more information about Trevena’s research?
More information about Trevena’s research and developments can be found on their official website: www.Trevena.com.
What are the primary focus areas of Trevena's research?
Trevena's primary research areas include treatments for acute and chronic pain, migraine, heart failure, and CNS disorders, based on innovative approaches targeting GPCRs.
TREVENA INC
Nasdaq:TRVN
TRVN Rankings
TRVN Stock Data
1.27M
850.11k
0.49%
14.34%
6.96%
Biotechnology
Pharmaceutical Preparations
United States of America
CHESTERBROOK